跳转至内容
Merck
CN

F8557

Sigma-Aldrich

FK866 盐酸盐 水合物

≥98% (HPLC), powder, NAD biosynthesis inhibitor

别名:

FK866盐酸盐 水合物, K22.175, (E)-N-[4-(1-苯甲酰哌啶-4-基)丁基]-3-(吡啶-3-基)丙烯酰胺

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C24H29N3O2·HCl · xH2O
分子量:
427.97 (anhydrous basis)
UNSPSC代码:
51111800
NACRES:
NA.77

product name

FK866 盐酸盐 水合物, ≥98% (HPLC)

质量水平

检测方案

≥98% (HPLC)

形式

powder

储存条件

desiccated

颜色

white to beige

溶解性

DMSO: 10 mg/mL, clear

储存温度

−20°C

InChI

1S/C24H29N3O2/c28-23(12-11-21-8-6-15-25-19-21)26-16-5-4-7-20-13-17-27(18-14-20)24(29)22-9-2-1-3-10-22/h1-3,6,8-12,15,19-20H,4-5,7,13-14,16-18H2,(H,26,28)/b12-11+

InChI key

KPBNHDGDUADAGP-VAWYXSNFSA-N

一般描述

FK866用于治疗炎症性疾病和癌症。

应用

FK866盐酸盐已用于:
  • 研究其对轴突内NAD+ 水平的影响
  • 诱导NAD +耗竭
  • 降低缺血性脑组织中肿瘤坏死因子-α (TNF-α)、烟酰胺磷酸核糖转移酶(NAMPT)和白介素6(IL-6)的水平

生化/生理作用

FK866是一种NAD生物合成的有效抑制剂,也是NAMPT(烟酰胺磷酸核糖基转移酶,内脂素,PBEF)的特异性抑制剂。NAMPT可作为细胞内和细胞外NAD生物合成酶起作用,其对于通过去乙酰化酶和其他消耗NAD的调节剂对代谢和应激抗性进行调节非常重要。NAMPT还可作为一种细胞因子(不依赖于其酶活性)在调节免疫反应中发挥重要作用。

象形图

Exclamation mark

警示用语:

Warning

危险声明

危险分类

Acute Tox. 4 Oral

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

FK866 compromises mitochondrial metabolism and adaptive stress responses in cultured cardiomyocytes
Oyarzun AP, et al.
Biochemical Pharmacology, 98(1), 92-101 (2015)
Zhongju Tan et al.
Annals of clinical and translational neurology, 7(5), 742-756 (2020-04-18)
FK866 is an inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), which exhibits neuroprotective effects in ischemic brain injury. However, in traumatic brain injury (TBI), the role and mechanism of FK866 remain unclear. The present research was aimed to investigate whether FK866 could
Nicotinamide riboside, a form of vitamin B3, protects against excitotoxicity-induced axonal degeneration
Chen CX, et al.
Neuroscience, 356, 193-206 (2017)
Phosphatidylserine is a marker for axonal debris engulfment but its exposure can be decoupled from degeneration
Shacham-Silverberg V, et al.
Cell Death & Disease, 9(11), 1116-1116 (2018)
Natasja Franceschini et al.
International journal of molecular sciences, 22(12) (2021-07-03)
For osteosarcoma (OS), the most common primary malignant bone tumor, overall survival has hardly improved over the last four decades. Especially for metastatic OS, novel therapeutic targets are urgently needed. A hallmark of cancer is aberrant metabolism, which justifies targeting

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门